Edifice Health

The core of Edifice Health's business is its proprietary "Inflammatory Age®" (iAge®) test, a biomarker metric that quantifies systemic chronic inflammation (SCI). This test evolved from the Stanford project, which demonstrated that SCI is a root cause and predictor of numerous age-related chronic diseases, including cancer, cardiovascular disease, and neurodegenerative disorders. By leveraging proteomics and artificial intelligence, the company analyzes blood-based biomarkers to generate a personalized iAge® score, indicating whether a person's immune health is older or younger than their chronological age. This provides a quantifiable measure of an individual's rate of aging.

The company's business model targets healthcare providers, clinics, and physicians focused on preventative medicine. Edifice provides these partners with the tools to measure, monitor, and manage their patients' inflammatory health. In addition to diagnostics, the company has identified and developed targeted interventions, such as dietary supplements, designed to improve an individual's inflammatory health based on their specific immunotype. Edifice also collaborates with pharmaceutical and food companies on research studies to explore the impact of SCI on various diseases and the potential for interventions.

A significant milestone was a $12 million funding round in April 2021, led by Leaps by Bayer, with participation from several other venture capital firms. This investment has supported the company's growth, talent acquisition, and the planned launch of consumer-centric products. The company is led by Chairman and CEO Wolfgang Daum, PhD, a serial life science entrepreneur.